A Phase 2 Study Comparing 2 Intermittent Dosing Schedules of Duvelisib in Participants With Indolent Non-Hodgkin Lymphoma

Summary

This study examined the effects of predefined 2-week duvelisib dose holidays on tumor responses and safety/tolerability.

Timeline

Start

2019-09-24

Primary completion

2023-07-24

Completion

2023-07-24

Drugs

Indications